Table 1.
Characteristics of studies selected for analysis.
| First author | Year | Study design | Number of patients | SexM/F | Age years | Intervention | Types of intervention | Tumor grade andmain features | Patient condition | Study period | Mean Follow up month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Su (12) | 2022 | Prospective, single-center | 30 | NA | NA | TACE+RT | Bigeminy therapy | NA (macroscopic vascular invasion) |
NA | 03.2018–05.2020 | NA |
| Song (13) | 2022 | Retrospective, single-center | 37 | NA | NA | TACE+TKI+ICI | Triple therapy | NA (vascular invasion, extrahepatic metastasis) |
Child–Pugh A/B, ECOG PS 0–1 |
12.2018–10.2020 | NA |
| Zhang (11) | 2022 | Prospective, multicenter | 38 | 35/3 | NA | TACE+TKI+ICI | Triple therapy | BCLC B/C | Child–Pugh A/B, ECOG PS 0–1 |
09.2020–05.2021 | 8.33 |
| Chen (1) (16) | 2021 | Retrospective, multicenter | 70 | 37/33 | 58 (36–69) | TACE+TKI+ICI | Triple therapy | BCLC B/C (no bile duct invasion, PVTT or symptomatic brain metastases) |
Child–Pugh A, ECOG PS 0–1 |
07.2016–07.2020 | 27 |
| Chen (2) (16) | 2021 | Retrospective, multicenter | 72 | 38/34 | 57 (35–68) | TACE+TKI | Bigeminy therapy | BCLC B/C (no bile duct invasion, PVTT or symptomatic brain metastases) |
Child–Pugh A, ECOG PS 0–1 |
07.2016–07.2020 | 27 |
| Li (1) (15) | 2021 | Retrospective, single-center | 42 | 37/5 | NA | cTACE | Monotherapy | BCLC A/B (no vascular invasion or extrahepatic metastasis) |
Child–Pugh A | 01.2015–07.2019 | 47.8 |
| Li (2) (15) | 2021 | Retrospective, single-center | 41 | 30/11 | NA | TACE+HAIC | Bigeminy therapy | BCLC A/B (no vascular invasion or extrahepatic metastasis) |
Child–Pugh A | 01.2015–07.2019 | 19.6 |
| Cai (17) | 2021 | Prospective, single-center | 32 | 20/12 | 60.0 ± 10.8 | DEB-TACE | Monotherapy | BCLC B (no vascular invasion, bile duct invasion or extrahepatic metastasis) |
Child–Pugh A/B | 05.2016–03.2017 | 35.4 |
| Wu (14) | 2021 | Retrospective, multicenter | 62 | 56/6 | 57 (23–75) | TACE+TKI+ICI | Triple therapy | BCLC A/B/C (vascular invasion, extrahepatic metastasis) |
Child–Pugh A, ECOG PS 0–1 |
11.2018–12.2020 | 12.2 |
| Chiu (1) (18) | 2020 | Retrospective, single-center | 19 | 18/1 | 63.7 (27.0–86.0) | cTACE | Monotherapy | BCLC A/B/C (no extrahepatic metastases or PVTT) |
Child–Pugh A/B, ECOG PS 0–1 |
01.2016–03.2019 | 12 |
| Chiu (2) (18) | 2020 | Retrospective, single-center | 42 | 32/10 | 67.4 (41.0–87.6) | DEB-TACE | Monotherapy | BCLC A/B/C (no extrahepatic metastases or PVTT) |
Child–Pugh A/B, ECOG PS 0–1 |
01.2016–03.2019 | 12 |
| Song (19) | 2019 | Retrospective, single-center | 652 | NA | NA | TACE+RT | Bigeminy therapy | NA (macroscopic vascular invasion) |
NA | 01.2010–02.2016 | 38 |
| Yoon (20) | 2018 | Prospective, single-center | 45 | 38/7 | 55 (42–77) | TACE+RT | Bigeminy therapy | BCLC A (vascular invasion or bile duct invasion; no extrahepatic metastasis) |
Child–Pugh A, ECOG PS 0–1 |
07.2013–10.2016 | 7.8 |
| Wu (1) (21) | 2018 | Retrospective, single-center | 30 | 27/3 | 52.83 ± 6.13 | cTACE | Monotherapy | BCLC B/C (no vascular invasion or extrahepatic metastasis) |
Child–Pugh A/B, ECOG PS 0–2 |
06.2016–02.2017 | 6 |
| Wu (2) (21) | 2018 | Retrospective, single-center | 24 | 22/2 | 56.25 ± 7.47 | DEB-TACE | Monotherapy | BCLC B/C (no vascular invasion or extrahepatic metastasis) |
Child–Pugh A/B, ECOG PS 0–2 |
06.2016–02.2017 | 6 |
| He (22) | 2017 | prospective, single-center | 41 | 37/4 | NA | cTACE | Monotherapy | BCLC A/B (no vascular invasion or extrahepatic metastasis) |
Child–Pugh A | 10.2015–10.2016 | NA |
| Zhang (23) | 2016 | Retrospective, single-center | 831 | NA | NA | cTACE | Monotherapy | NA (no extrahepatic metastasis or PVTT) |
Child–Pugh A/B, ECOG PS 0–2 |
06.2004–12.2014 | 42.2 |
| Shi (24) | 2012 | Prospective, single-center | 420 | NA | NA | cTACE | Monotherapy | NA (too bulky for resection or situated centrally at the hepatic hilus, macroscopic vascular invasion) |
Child–Pugh A/B | 01.2004–12.2008 | 48 |
TACE, transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; RT, radiotherapy; HAIC, hepatic arterial infusion chemotherapy; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not available; M, male; F, female.